Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2021-06-11 Director's Dealing
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It identifies a specific board member (Jens Peter Stenvang) and details a transaction involving financial instruments (Warrants/Restricted Share Units). This is a classic insider dealing disclosure, which falls under the 'Director's Dealing' category.
2021-06-11 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It identifies a specific board member (Gertrud Koefoed Rasmussen) and details a transaction involving financial instruments (Warrants/Restricted Share Units). This is a classic insider dealing/director's dealing notification.
2021-06-11 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document is an announcement regarding transactions in company shares by persons discharging managerial responsibilities (PDMRs). This is a classic 'Director's Dealing' notification. Although the document mentions attachments, the primary purpose of the text is to disclose the insider trading activity as required by regulatory standards, fitting the definition of DIRS.
2021-06-11 English
Share Issue/Capital Change 2021
Share Issue/Capital Change Classification · 99% confidence The document explicitly states that Zealand Pharma has increased its share capital as a consequence of the exercise of employee warrants, resulting in the issuance of 89,996 new shares. This action directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). Although it involves warrants (which can sometimes be related to financing/CAP), the core event being reported is the resulting issuance of new shares and the corresponding amendment to the Articles of Association regarding the total share capital. It is not a general announcement of a financing round (CAP) or a dividend notice (DIV).
2021-06-10 English
Regulatory Filings 2021
Regulatory Filings Classification · 100% confidence The document is a press release announcing that the FDA granted Fast Track Designation to a drug candidate (BI 456906) developed by Boehringer Ingelheim and Zealand Pharma for NASH treatment. It details the significance of the designation, provides background on the drug and the disease, and includes standard company boilerplate information. This type of announcement, focusing on regulatory milestones and clinical development updates, is typically classified as an Earnings Release (ER) if it contains key financial highlights, or more generally as a Regulatory Filing (RNS) if it's a specific, non-financial regulatory event announcement. Since it is a specific announcement about a regulatory action (FDA designation) and not a comprehensive financial report (like 10-K or IR) or a general earnings summary (ER), and it doesn't fit other specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate general category for a specific, non-financial regulatory update that isn't a standard financial report is Regulatory Filings (RNS). However, given the context of drug development milestones, it often functions similarly to an Earnings Release in terms of market impact, but RNS is the best fit for a general regulatory update announcement that isn't a core financial report.
2021-06-02 English
Total number of shares and voting rights in Zealand Pharma at May 31, 2021
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from Zealand Pharma regarding the total number of shares and voting rights as of May 31, 2021, following a capital increase. This type of disclosure is a standard regulatory requirement under the Danish Capital Markets Act. While it relates to share capital, it is specifically a notification of the total voting rights and share count rather than a new share issuance event (SHA) or a transaction in own shares (POS). Given the nature of the disclosure as a mandatory regulatory update, it fits best under the RNS (Regulatory Filings) category.
2021-05-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.